Search Results
May 05, 2026, 08:30 ET Viralgen s'associe à Elaaj Bio afin de faire progresser le programme de thérapie génique pour le trouble du déficit en CDKL5
LONDRES, 5 mai 2026 /PRNewswire/ -- Viralgen, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan spécialisée dans les thérapies géniques par virus adéno-associé recombinant (rAAV), a annoncé aujourd'hui un partenariat avec Elaaj
More news about: Viralgen
May 05, 2026, 08:00 ET VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
critical path to BLA filing, including bridging studies designed to confirm that Entolimod™ manufactured at Velocity Bioworks, Valion Bio's wholly owned CDMO subsidiary in San Antonio, is equivalent to drug material previously evaluated. Entolimod™ has been administered in 42 non-human primate studies and
More news about: Tivic Health Systems, Inc.
May 05, 2026, 07:30 ET PackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026
[email protected] PackGenePackGene is a leading AAV vector CRO/CDMO offering economical, reliable, scalable plasmid DNA and AAV vector production from early discovery through clinical trials in cell and gene therapy.
More news about: Packgene
May 05, 2026, 07:00 ET Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
EcoVadis Platinum rating and also won a sustainability award at the CDMO Leadership Awards.About Samsung Biologics Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery
More news about: Samsung Biologics
May 05, 2026, 07:00 ET TopGum Completes U.S. Acquisition of PL Developments Valued at Up to USD 35 Million
DevelopmentPL Developments is a family-owned U.S. pharmaceutical and consumer healthcare contract development and manufacturing organization (CDMO) headquartered in Westbury, New York and Miami, Florida. PLD develops, manufactures, packages, and distributes more than 450 products across over 2,000
More news about: TopGum Industries, Inc.
May 05, 2026, 02:00 ET DIE EXPANSION UND DAS WACHSTUM VON ESTEVE IN DER EU SOWIE IN DEN USA BESCHLEUNIGEN DIE TRANSFORMATION ZU EINEM GLOBALEN GESUNDHEITSUNTERNEHMEN
Industriestandorte im CDMO-Bereich in Spanien und China zurückzuführen ist.In den vergangenen zwei Jahren wurden von ESTEVE 500 Millionen Euro dafür eingesetzt, die Versorgung von Patientinnen und Patienten mit hochspezialisiertem Behandlungsbedarf weltweit zu verbessern und die CDMO-Kompetenzen
More news about: ESTEVE
May 05, 2026, 02:00 ET L'EXPANSION ET LA CROISSANCE D'ESTEVE DANS L'UE ET AUX ÉTATS-UNIS ACCÉLÈRENT SA TRANSFORMATION EN UNE ENTREPRISE MONDIALE DE SOINS DE SANTÉ
Les nouveaux actifs dans les deux secteurs d'activité - pharmaceutique et CDMO - soutiennent une croissance à deux chiffres des revenus nets et du BAIIA et témoignent d'une exécution solide de la stratégieDes acquisitions ciblées et une intégration rapide élargissent
More news about: ESTEVE
May 04, 2026, 16:05 ET Valion Bio Appoints Melinda Lackey as General Counsel
appointment comes as Valion Bio is in the process of advancing Entolimod™ toward an FDA Animal Rule approval pathway for ARS, and scaling its wholly owned CDMO subsidiary Velocity Bioworks in San Antonio. Ms. Lackey's transactional, IP, and public company governance experience positions her to support all of
More news about: Valion Bio, Inc.
May 04, 2026, 12:03 ET ProBio De-Risks Cell & Gene Therapy with New Packaging Test
ProBio CDMO - Biologics and CGT CDMO Services]. About ProBio CDMO ProBio CDMO is a global contract development and manufacturing organization specializing in cell and gene therapies.
More news about: ProBio Inc
May 04, 2026, 11:49 ET ESTEVE'S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY
businesses – Pharma and CDMO – fuel double-digit growth in net revenues and EBITDA and prove strong strategy executionTargeted acquisition and rapid integration expand ESTEVE pharma business portfolio with eight new products in the last 18 monthsCDMO business grows with new
More news about: ESTEVE
May 04, 2026, 07:00 ET ROIS establishes itself as Global CDMO with US Expansion
ROIS CDMO closes the acquisition of US injectable manufacturing facility to strengthen global capacityPHOENIX, May 4, 2026 /PRNewswire/ -- ROIS, a Global CDMO with its routes in Spain, announced
More news about: ROIS
May 04, 2026, 07:00 ET AVISTA HEALTHCARE PARTNERS LAUNCHES BIRCHWELL CONSUMER HEALTH AS NEW OVER-THE-COUNTER PLATFORM; ACQUIRES BAG BALM AS FIRST INVESTMENT
Europe; Vision Healthcare, a market‑leading digitally enabled VMS platform in Europe; and Trillium Health Care Products, a leading North American OTC CDMO serving blue‑chip pharmaceutical, OTC, and CPG companies. Prior consumer healthcare investments include Arcadia Consumer Healthcare and Trimb Healthcare.
More news about: Avista Healthcare Partners
May 01, 2026, 00:35 ET Piramal Pharma Limited annuncia i risultati del quarto trimestre e dell'intero esercizio 2026
(3) % CDMO1,708
More news about: Piramal Pharma Limited
Apr 30, 2026, 16:19 ET Piramal Pharma Limited、FY26第4四半期および通期決算を発表
(3) % CDMO1,708
More news about: Piramal Pharma Limited
Apr 30, 2026, 16:10 ET Piramal Pharma Limited annonce ses résultats pour le quatrième trimestre et l'exercice 2026
(3) % CDMO1 708
More news about: Piramal Pharma Limited
Apr 30, 2026, 12:34 ET Piramal Pharma Limited gibt Ergebnisse für das vierte Quartal und das Gesamtjahr des Geschäftsjahres 2026 bekannt
(3) % CDMO1.708
More news about: Piramal Pharma Limited
Apr 30, 2026, 11:53 ET L'ESPANSIONE E LA CRESCITA DI ESTEVE IN EUROPA E NEGLI STATI UNITI NE ACCELERANO LA TRASFORMAZIONE IN AZIENDA FARMACEUTICA GLOBALE
settore CDMO. L'acquisizione di Regis Technologies negli Stati Uniti ha rappresentato una pietra miliare fondamentale, aggiungendo capacità di sviluppo in fase uno ed estendendo la presenza dell'azienda nel più grande mercato farmaceutico del mondo. Questa mossa rafforza la capacità CDMO di ESTEVE
More news about: ESTEVE
Apr 30, 2026, 11:47 ET Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing
continue progressing toward becoming a leading cell therapy CDMO partner."Board of DirectorsSYED T. HUSAINSyed T. Husain serves as Chairman and Chief Executive Officer of Made Scientific, bringing deep experience across the CDMO spectrum from development through commercialization of established
More news about: Made Scientific, Inc.
Apr 30, 2026, 08:30 ET Pinnaql Acquires Pharma Resource Group, Further Expanding Scientific and Manufacturing Advisory Capabilities
PinnaqlPinnaql (an LSOMS Holdings company) provides quality, regulatory, and operational excellence consulting to biopharmaceutical, medical device, and CDMO companies worldwide. The company's mission is to deliver expert-driven, compliant solutions that empower clients to accelerate innovation and improve
More news about: 3 Boomerang Capital
Apr 30, 2026, 07:16 ET La expansión de ESTEVE en EU y EEUU impulsa crecimiento y consolidación como farmacéutica global
crecimiento en CDMO. La adquisición de Regis Technologies en Estados Unidos marcó un hito clave, al incorporar capacidades de desarrollo en fases tempranas y ampliar la presencia de la compañía en el mayor mercado farmacéutico del mundo. Este movimiento refuerza la capacidad de ESTEVE CDMO para ofrecer
More news about: ESTEVE
Apr 30, 2026, 07:15 ET A EXPANSÃO E O CRESCIMENTO DA ESTEVE NA UE E NOS EUA ACELERAM A SUA TRANSFORMAÇÃO NUMA EMPRESA DE CUIDADOS DE SAÚDE GLOBAL
crescimento de CDMO. A aquisição da Regis Technologies nos Estados Unidos assinalou um marco importante, acrescentando capacidades de desenvolvimento em fase inicial e alargando a presença da empresa no maior mercado farmacêutico do mundo. Esta medida reforça a capacidade da ESTEVE CDMO de apoiar os
More news about: ESTEVE
Apr 30, 2026, 07:12 ET ESTEVE'S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY
businesses – Pharma and CDMO – fuel double-digit growth in net revenues and EBITDA and prove strong strategy executionTargeted acquisition and rapid integration expand ESTEVE pharma business portfolio with eight new products in the last 18 monthsCDMO business grows with new
More news about: ESTEVE
Apr 29, 2026, 14:27 ET Piramal Pharma Limited anuncia los resultados del cuarto trimestre y del ejercicio fiscal 2026
(3) % CDMO1.708
More news about: Piramal Pharma Limited
Apr 29, 2026, 07:00 ET LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
industry-leading CDMO capabilities and capacity for ophthalmics, powering the future of drug delivery in this field in North America. We look forward to extending our purpose - We CARE. We CREATE. We DELIVER -towards an even wider group of customers, therapies and patients."The expanded CDMO services
More news about: LTS Lohmann Therapie-Systeme AG
Apr 29, 2026, 07:00 ET LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
industry-leading CDMO capabilities and capacity for ophthalmics, powering the future of drug delivery in this field in North America. We look forward to extending our purpose - We CARE. We CREATE. We DELIVER -towards an even wider group of customers, therapies and patients."The expanded CDMO services
More news about: LTS Lohmann Therapie-Systeme AG